No connection

Search Results

ALHC vs INDV

ALHC
Alignment Healthcare, Inc.
BEARISH
Price
$19.22
Market Cap
$3.85B
Sector
Healthcare
AI Confidence
85%
INDV
Indivior Pharmaceuticals, Inc.
NEUTRAL
Price
$30.54
Market Cap
$3.82B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ALHC
--
INDV
18.62
Forward P/E
ALHC
26.79
INDV
8.87
P/B Ratio
ALHC
21.89
INDV
-38.95
P/S Ratio
ALHC
0.97
INDV
3.08
EV/EBITDA
ALHC
80.67
INDV
10.01

Profitability

Gross Margin
ALHC
12.37%
INDV
84.02%
Operating Margin
ALHC
-1.01%
INDV
37.15%
Profit Margin
ALHC
-0.02%
INDV
16.95%
ROE
ALHC
-0.7%
INDV
--
ROA
ALHC
1.0%
INDV
19.22%

Growth

Revenue Growth
ALHC
44.4%
INDV
19.7%
Earnings Growth
ALHC
--
INDV
376.2%

Financial Health

Debt/Equity
ALHC
1.84
INDV
--
Current Ratio
ALHC
1.71
INDV
0.71
Quick Ratio
ALHC
1.54
INDV
0.49

Dividends

Dividend Yield
ALHC
--
INDV
--
Payout Ratio
ALHC
0.0%
INDV
0.0%

AI Verdict

ALHC BEARISH

ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.

Strengths
Strong revenue growth of 44.4% YoY, indicating market expansion and execution capability
Exceptional earnings surprise history with average 458.81% beat in last 4 quarters
Positive recent EPS growth (Q/Q: +42.9%, YoY: +171.4%) signaling improving profitability trajectory
Risks
Piotroski F-Score of 2/9 indicates severe financial distress signals and weak operational efficiency
Negative ROE (-0.70%) and ROA (1.00%) reflect poor capital utilization and unprofitability
Debt/Equity ratio of 1.84 is high, especially for a loss-making company with no clear path to profitability
INDV NEUTRAL

INDV presents a stark contrast between operational excellence and financial fragility, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits explosive earnings growth (376% YoY) and trades significantly below its intrinsic value of $48.38, its balance sheet is highly distressed with a negative Price/Book ratio of -38.95 and a Current Ratio of 0.71. The forward P/E of 8.87 suggests an attractive valuation for growth, but the underlying solvency risks prevent a bullish rating. The investment thesis relies entirely on continued high-margin growth to offset structural financial weaknesses.

Strengths
Exceptional gross margins (84.02%) and operating margins (37.15%)
Explosive YoY earnings growth of 376.20%
Strong earnings track record with 3/4 recent quarters beating estimates
Risks
Severe financial health warning indicated by Piotroski F-Score of 2/9
Negative shareholders' equity as evidenced by Price/Book of -38.95
Liquidity risk with a Current Ratio (0.71) and Quick Ratio (0.49) well below 1.0

Compare Another Pair

ALHC vs INDV: Head-to-Head Comparison

This page compares Alignment Healthcare, Inc. (ALHC) and Indivior Pharmaceuticals, Inc. (INDV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile